本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 规定，公司应当在回购期间每个月的前三个交易日内披露截至上月末的回购进展 情况。现将公司截至上月末的回购股份进展情况公告如下： 一、回购公司股份的进展情况 证券代码 ...

Core Insights - Haisheng Pharmaceutical reported a revenue of 1.938 billion yuan for 2024, a year-on-year decline of 10.75% [1] - The company recorded a net loss attributable to shareholders of 330 million yuan, narrowing by 21.38% year-on-year [1] - The basic earnings per share stood at -0.21 yuan [1] Financial Performance - The decline in performance was primarily due to multiple factors impacting the pharmaceutical and dye industries, with intense market competition leading to price pressures [4] - Total assets at the end of 2024 were 7.456 billion yuan, down 0.85% year-on-year, while total liabilities increased by 21.2% to 2.324 billion yuan, resulting in a debt-to-asset ratio of 31.2% [4] - The net cash flow from operating activities was 175 million yuan, a decrease of 27.31% year-on-year, mainly due to increased asset impairment losses and depreciation [4] - Cash flow from financing activities saw a significant decline of 96.51%, while cash flow from investing activities worsened from -128 million yuan to -527 million yuan [4] Business Segments - The pharmaceutical segment generated revenue of 1.368 billion yuan, down 11.77% year-on-year, accounting for 70.59% of total revenue [4] - The dye segment reported revenue of 551 million yuan, a decline of 8.80%, representing 28.47% of total revenue [4] - Key products in the dye segment, such as Reactive Brilliant Blue KN-R, maintained a high market share with double-digit sales growth [4] Research and Development - R&D expenditure for 2024 was 129 million yuan, constituting 6.68% of total revenue [5] - The company is focusing on the development of specialty APIs, generics, and innovative drugs, with new projects like a peptide platform and expansion into ophthalmic, psychiatric, and cardiovascular applications [5]

Group 1 - The company raised a total of RMB 1,026.87 million through a non-public offering of 99.89 million shares at a price of RMB 10.28 per share, with net proceeds amounting to RMB 1,014.40 million after deducting fees [2][3] - The company has established a dedicated account for the management of raised funds, signing tripartite and quadripartite supervision agreements with relevant banks and sponsors to ensure proper fund usage [3][4] - As of December 31, 2024, the company maintained one dedicated account for the raised funds [4] Group 2 - The company reported that the actual use of raised funds has been delayed for several projects, including the "Pharmaceutical Comprehensive R&D Center" and "Environmental Facility Renovation Project," due to strategic adjustments and external factors [5][6] - The "Pharmaceutical Comprehensive R&D Center" project was transferred to a subsidiary, and the implementation location was changed, leading to delays in investment progress [5][6] - The company stated that the benefits of certain projects cannot be individually accounted for, as their effectiveness is reflected indirectly through product quality improvements [7][10] Group 3 - The company reported a net loss of RMB 330.27 million for the year 2024, with total revenue of RMB 1,938.47 million [24][28] - The company proposed not to distribute cash dividends for 2024 due to the reported losses, aligning with its dividend policy [28] - The company has established a robust internal control system, ensuring compliance with relevant laws and regulations [31]

Core Viewpoint - Zhejiang Haixiang Pharmaceutical Co., Ltd. faces significant challenges in 2024, including declining revenue, increased competition, and a need to enhance profitability despite some improvements in financial metrics [1] Financial Performance Summary - Revenue decreased to 1,938,465,657.86 CNY in 2024, down 10.75% from 2,171,886,869.45 CNY in 2023, indicating competitive pressure in both pharmaceutical and dye sectors [2] - Net loss narrowed to -330,267,195.37 CNY, an improvement of 21.38% from -420,055,857.71 CNY in 2023, but the company remains in a loss position [3] - Basic and diluted earnings per share were both -0.21 CNY, showing a 19.23% improvement from -0.26 CNY in 2023, yet still reflect poor shareholder returns [4] Expense Analysis - Sales expenses increased by 13.81% to 33,253,110.97 CNY, indicating a greater investment in market promotion, although this has not yet translated into revenue growth [5] - Management expenses decreased by 5.36% to 307,458,090.96 CNY, suggesting effective internal management and cost control [6] - Financial expenses significantly dropped by 91.79% to -60,065,121.40 CNY, primarily due to increased exchange gains, positively impacting profits [7] Research and Development - R&D expenses rose by 12.01% to 129,445,758.14 CNY, reflecting the company's commitment to innovation across various product lines [8] Cash Flow Analysis - Net cash flow from operating activities decreased by 27.31% to 174,834,870.57 CNY, indicating weakened cash generation capabilities [9] - Net cash flow from investing activities worsened by 311.34% to -527,393,406.00 CNY, necessitating a review of investment strategies [10] - Net cash flow from financing activities fell by 96.51% to 3,461,869.72 CNY, highlighting financial pressure and the need for careful cash management [11]

浙江海翔药业股份有限公司 2024年度独立董事述职报告（钱建民） 作为浙江海翔药业股份有限公司(以下简称"公司")的第七届董事会独立董 事，本人严格按照《公司法》《上市公司独立董事管理办法》等相关法律法规和 《公司章程》《独立董事工作制度》的规定和要求，诚信、勤勉、独立地履行职 责，积极关注公司的经营业务及发展情况，切实维护公司整体利益以及全体股东 特别是中小股东的合法权益，本人现就2024年度独立董事履职情况述职如下： 一、基本情况 报告期内，本人任职情况均符合《上市公司独立董事管理办法》第六条规定 的独立性要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席会议的情况 1、出席董事会及股东大会情况 2024年度，公司共召开5次董事会会议，2次股东大会。本人出席会议情况如 下表： | 本报告期 | | 以通讯方 | | | 是否连续 | | | --- | --- | --- | --- | --- | --- | --- | | | 现场出 | | 委托出 | 缺席次 | 两次未亲 | 出席股东 | | 应参加董 | 席次数 | 式参加次 | 席次数 | 数 | 自参加会 | 大会次数 | | 事 ...

浙江海翔药业股份有限公司 2024年度独立董事述职报告（梁超） 作为浙江海翔药业股份有限公司(以下简称"公司")的第七届董事会独立董 事，本人严格按照《公司法》《上市公司独立董事管理办法》等相关法律法规和 《公司章程》《独立董事工作制度》的规定和要求，诚信、勤勉、独立地履行职 责，积极关注公司的经营业务及发展情况，切实维护公司整体利益以及全体股东 特别是中小股东的合法权益，本人现就2024年度独立董事履职情况述职如下： 一、基本情况 本人梁超，中国国籍，无境外永久居留权，硕士研究生，中共党员，注册会 计师。曾就职于招商证券股份有限公司投行部门，浙江省台州市路桥区发展和改 革局财务部、海洋经济办公室，台州学院财务管理系专任教师，台州市资产管理 有限公司副总经理。现任台州学院金融系教师，浙江富华睿银投资管理有限公司 战略投资部总经理、台州市环境科学设计研究院有限公司董事。2022年11月30日 起担任公司独立董事。 报告期内，本人任职情况均符合《上市公司独立董事管理办法》第六条规定 的独立性要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席会议的情况 1、出席董事会及股东大会情况 2024年度，公司共召 ...

浙江海翔药业股份有限公司 2024年度独立董事述职报告（俞永平） 作为浙江海翔药业股份有限公司(以下简称"公司")的第七届董事会独立董 事，本人严格按照《公司法》《上市公司独立董事管理办法》等相关法律法规和 《公司章程》《独立董事工作制度》的规定和要求，诚信、勤勉、独立地履行职 责，积极关注公司的经营业务及发展情况，切实维护公司整体利益以及全体股东 特别是中小股东的合法权益，本人现就2024年度独立董事履职情况述职如下： 一、基本情况 本人俞永平，中国国籍，美国永久居留权，理学博士。浙江大学药学院教授， 博士生导师，历任浙江大学药物研究所所长、药学院副院长、学术委员会副主任， 教育部"新世纪优秀人才"，浙江省"新世纪151人才工程"第一层次培养计划。 主持研发的创新药物已分别进入临床 I 期和 II 期研究。作为负责人承担"十一 五"、"十二五"国家重大科技专项-重大新药创制、科技部中印尼生物技术联 合实验室中方负责人，国家自然科学基金重大研究计划项目、国家自然科学基金 面上项目、浙江省自然科学基金重大项目、企业联合研发项目等科研项目20余项。 发表 SCI 论文100余篇，参与编写专著5部，授权美国、欧洲、 ...

浙江海翔药业股份有限公司 舆情管理制度 第一章 总则 第一条 为了提高浙江海翔药业股份有限公司（以下简称"公司"）应对各 类舆情的能力，建立快速反应和应急处置机制，及时妥善处理各类舆情对公司 股价、商业信誉以及正常生产经营活动造成的影响，切实保护投资者合法权 益，根据《深圳证券交易所股票上市规则》等相关法律、行政法规和规范性文 件的相关规定以及《公司章程》要求，结合公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面、不实报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的 信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第三条 本制度所称舆情分为重大舆情与一般舆情： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活 动，使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易 价格变动的负面舆情； （二）一般舆情：指除重大舆情之外的其他舆情。 第二章 舆情管理的组织体系及其工作职责 第四条 公司应对各类舆情实 ...

Financial Performance - The company reported a basic earnings per share of -0.2100 yuan for 2024, an improvement of 19.23% compared to -0.2600 yuan in 2023 [1] - The total revenue decreased to 19.38 billion yuan in 2024, down 10.77% from 21.72 billion yuan in 2023 [1] - The net profit for 2024 was -3.3 billion yuan, showing a 21.43% improvement from -4.2 billion yuan in 2023 [1] - The return on equity was -6.19% in 2024, an improvement from -7.18% in 2023 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 80,509.77 million shares, accounting for 49.83% of the circulating shares, with a decrease of 1,685.38 million shares compared to the previous period [1] - Zhejiang Donggang Industrial Co., Ltd. remains the largest shareholder with 52,398.26 million shares, representing 32.43% of the total share capital, unchanged from the previous period [2] - The employee stock ownership plan of Zhejiang Haixiang Pharmaceutical Co., Ltd. saw a reduction of 197.72 million shares, now holding 2,952.37 million shares [2] Dividend Policy - The company has decided not to distribute dividends or increase capital [1]

浙江海翔药业股份有限公司 关于对天健会计师事务所 2024 年度履职情况评估报告 浙江海翔药业股份有限公司（以下简称"公司"）聘请天健会计师事务所 （特殊普通合伙）（以下简称"天健会计师事务所"）作为公司 2024 年度年报 审计机构。根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司治理准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交 易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等规定和要 求，公司对天健会计师事务所 2024 年度审计过程中的履职情况进行评估，具体 情况如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 7 月 组织形式 | 年 | 18 | 日 | | | | | | 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 128 | | | | | ...